New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 7, 2014
06:06 EDTCYTRCytRx's aldoxorubicin for sarcomashows positive Phase 2b clinical trial results
CytRx's oral presentation titled “Randomized phase 2b trial comparing first-line treatment with aldoxorubicin versus doxorubicin in patients with advanced soft tissue sarcomas,” was featured in The Lancet Oncology in its July issue. The updated results from CytRx’s ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable STS demonstrated that aldoxorubicin significantly increases progression-free survival, PFS at 6 months, overall response rate and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. The data trended in favor of aldoxorubicin for all of the major subtypes of STS. The company is on track to report the full overall survival results from this trial prior to year-end.
News For CYTR From The Last 14 Days
Check below for free stories on CYTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
06:06 EDTCYTRCytRx begins enrollment for Phase 1b clinical trial of aldoxorubicin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use